Collagen Solutions Plc (AIM:COS) is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics.
Collagen Solutions Plc was established and admitted to the London Stock Exchange on the 2nd January 2014 when Collbio Limited acquired the assets of Collagen Solutions LLC and went through a simultaneous reverse takeover into Healthcare Investment Opportunities plc, which became Collagen Solutions Plc. On 10th December 2014, by way of reverse takeover, Collagen Solutions Plc, acquired Southern Lights Biomaterials based in New Zealand, being a logical strategic extension and complementary in nature to the Group’s existing business model.
Collagen Solutions provides customers with medical grade collagen products and development services to create collagen components from concept to clinical trial stage, including technology transfer and contract manufacturing.